<DOC>
	<DOCNO>NCT01834950</DOCNO>
	<brief_summary>The study single arm prospective study , aim identify biomarkers early response trastuzumab . It prognostic factor study recruit consecutive case HER-2 positive breast cancer eligible pre-operative treatment trastuzumab , follow breast conserve surgery . The investigator study association value biomarkers measure diagnosis Response Evaluation Criteria Solid Tumors response ( partial complete response ) use logistic regression ( main analysis ) .</brief_summary>
	<brief_title>Identification Early Markers Response Resistance Trastuzumab</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Signed write informed consent Female patient age 18 year old . Histologically confirm untreated invasive carcinoma breast Previous treat invasive breast carcinoma ductal carcinoma situ allow , assume evidence disease moment inclusion protocol , patient current treatment Candidates breast conserve surgery : patient minimum size 11 mm measure breast US . Bilateral multifocal tumor allow , assume biopsy pre posttreatment perform target lesion . HER2positive ( define either immunohistochemistry [ immunohistochemistry ] 3+ situ hybridization [ ISH ] positive ) assess local laboratory primary tumor ( ISH positivity define ratio 2.2 great number HER2 gene copy number signal abnormality chromosome 17 ( CEP17 ) , single probe test , HER2 gene count great 4 ) and/or PCR . No evidence metastatic disease Eastern Cooperative Oncology Group ( ECOG ) performance status 0/1 . Left ventricular ejection fraction ( LVEF ) least 50 % Negative pregnancy test woman childbearing potential ( premenopausal less 12 month amenorrhea postmenopause , undergone surgical sterilization ) . For woman childbearing potential sexually active , agreement use highly effective , nonhormonal form contraception two effective form nonhormonal contraception least 6 month posttreatment . Maximum time allow collect inform consent first administration treatment :21 day All patient candidate initial surgery candidate primary chemotherapy ( T3 acceptable multifocal decision primary surgery ) . Patients noncandidate initial breast surgery patient 's candidate neoadjuvant chemotherapy ; Patients receive another concomitant anticancer treatment like chemotherapy , immunotherapy , antiHER2 treatment trastuzumab , endocrine treatment , radiotherapy ; Known hypersensibility trastuzumab ; Serious uncontrolled concomitant disease would contraindicate use trastuzumab would put patient high risk treatmentrelated complication ; Inadequate organ function , evidence follow laboratory result : Absolute neutrophil count &lt; 1,500 cells/mm3 Platelet count &lt; 100,000 cells/mm3 Hemoglobin &lt; 9 g/dL Total bilirubin great upper limit normal ( ULN ) ( unless patient document Gilbert 's syndrome ) Aspartate aminotransferase ( AST [ SGOT ] ) alanine aminotransferase ( ALT [ SGPT ] ) &gt; 2.5 x ULN Serum creatinine &gt; 2.0 mg/dL 177 Î¼mol/L International normalize ratio ( INR ) activate partial thromboplastin time ( aPTT ) partial thromboplastin time ( PTT ) &gt; 1.5 x ULN ( unless therapeutic coagulation ) Uncontrolled hypertension ( systolic &gt; 150 mmHg and/or diastolic &gt; 100 mmHg ) clinically significant ( i.e . active ) cardiovascular disease : cerebrovascular accident/stroke myocardial infarction within 6 month prior first study medication ; unstable angina ; CHF New York Heart Association ( NYHA ) Grade II high ; serious cardiac arrhythmia require medication ; Current know infection human immunodeficiency virus ( HIV ) , hepatitis B C virus ; Assessed investigator unable unwilling comply requirement protocol ; Pregnant breastfeeding patient ;</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>